Teva to commercialize Prestige's Herceptin biosimilar in Europe

21 October 2025

Israeli pharma major Teva Pharmaceutical Industries (NYSE: TEVA) has entered a licensing agreement with Singapore-based Prestige Biopharma (Kosdaq: 950210) to commercialize Tuznue (trastuzumab), a biosimilar of Roche’s (ROG: SIX) Herceptin, across most European markets. Teva will lead marketing and distribution, while Prestige manages production at its EU-GMP-certified facilities.

Approved by the European Commission in September 2024, Tuznue is indicated for HER2-positive breast and gastric cancers. Teva plans to leverage its extensive commercial infrastructure to accelerate launches across Europe, expanding its biosimilar portfolio and oncology presence. The deal underscores Teva’s ongoing shift away from generics toward higher-value specialty and biosimilar products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK